SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana
2007

SAVVY Gel for HIV Prevention in Women

Sample size: 2142 publication Evidence: low

Author Information

Author(s): Peterson Leigh, Nanda Kavita, Opoku Baafuor Kofi, Ampofo William Kwabena, Owusu-Amoako Margaret, Boakye Andrew Yiadom, Rountree Wes, Troxler Amanda, Dominik Rosalie, Roddy Ronald, Dorflinger Laneta

Primary Institution: Family Health International, Durham, North Carolina, United States

Hypothesis

The trial aimed to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk.

Conclusion

SAVVY was not associated with increased adverse events overall, but was associated with higher reporting of reproductive adverse events.

Supporting Evidence

  • 2142 HIV-negative women were enrolled in the study.
  • The study was conducted in Accra and Kumasi, Ghana.
  • Participants made up to 12 monthly visits for HIV testing and product supply.
  • Seventeen HIV seroconversions occurred; eight in the SAVVY group and nine in the placebo group.
  • The overall HIV incidence rate was 1.09 per 100 person years.
  • More participants in the SAVVY group reported reproductive tract adverse events than in the placebo group.
  • The study was terminated early due to lower-than-expected HIV incidence.
  • Participants reported using the gel for an average of 75% of coital acts.

Takeaway

The study tested a gel to see if it could help prevent HIV in women, but it didn't show that it worked better than a placebo.

Methodology

This was a Phase 3, double-blind, randomized, placebo-controlled trial with 2142 HIV-negative women at high risk of HIV infection.

Potential Biases

Participants may have engaged in safer behaviors due to being in a clinical trial, which could affect the results.

Limitations

The study was terminated early due to lower-than-expected HIV incidence, which limited the ability to assess effectiveness.

Participant Demographics

Participants were young, HIV-negative women aged 18 to 35, primarily unmarried with fewer than 9 years of education.

Statistical Information

P-Value

0.731

Confidence Interval

0.33, 2.27

Statistical Significance

p=0.731

Digital Object Identifier (DOI)

10.1371/journal.pone.0001312

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication